FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916033262> ?p ?o ?g. }

• W2916033262 endingPage "499" @default.
• W2916033262 startingPage "489" @default.
• W2916033262 abstract "Abstract Purpose Incretin‐based medications are a novel class of agents for the treatment of type‐2 diabetes mellitus (DM2). The safety profile of these medications is not firmly established, and concerns have been raised about their potential carcinogenicity. The objective of our study was to produce new evidence on the effect of incretin‐based medications on cancer risk in patients with DM2. Methods We conducted a “retrospective cohort” study with data from the Clinical Practice Research Datalink and the Hospital Episodes Statistics in the UK. New users of either an incretin‐based medication ( n = 18 885) or a sulfonylurea medication ( n = 36 929) between 2007 and 2013 were identified and followed for up to 8 years. Cox proportional‐hazards models were used to estimate the quasi‐intention‐to‐treat and quasi‐per‐protocol hazard‐ratios for the association between incretin‐based medications with cancer while adjusting for potential confounders. Results The adjusted hazard ratio (95% confidence interval) for use of incretin‐based medications versus use of sulfonylurea medications for the overall‐cancer outcome was 0.97 (0.90, 1.05) in the quasi‐intention‐to‐treat analysis and 0.90 (0.81, 1.00) in the quasi‐per‐protocol analysis. In both analyses, the hazard‐ratio functions over the 8‐year follow‐up seemed fairly constant, and the 8‐year cumulative‐risk functions in the two subcohorts were similar. Conclusions Our study suggests that the use of incretin‐based medications in patients with DM2 does not increase the risk of cancer relative to the use of sulfonylurea medications, at least in the first several years of the use. Further research is needed to assess long‐term effects of the use of incretin‐based medications on cancer risk." @default.
• W2916033262 created "2019-03-02" @default.
• W2916033262 creator A5056369963 @default.
• W2916033262 creator A5059182035 @default.
• W2916033262 creator A5089899558 @default.
• W2916033262 date "2019-02-18" @default.
• W2916033262 modified "2023-10-02" @default.
• W2916033262 title "Does the use of incretin‐based medications increase the risk of cancer in patients with type‐2 diabetes mellitus?" @default.
• W2916033262 cites W1552936749 @default.
• W2916033262 cites W1577118500 @default.
• W2916033262 cites W1768177901 @default.
• W2916033262 cites W1964098393 @default.
• W2916033262 cites W1967256054 @default.
• W2916033262 cites W1976838333 @default.
• W2916033262 cites W1977144451 @default.
• W2916033262 cites W1977950682 @default.
• W2916033262 cites W1978209044 @default.
• W2916033262 cites W2004409542 @default.
• W2916033262 cites W2008055393 @default.
• W2916033262 cites W2011601530 @default.
• W2916033262 cites W2016193795 @default.
• W2916033262 cites W2022096337 @default.
• W2916033262 cites W2027081774 @default.
• W2916033262 cites W2044763202 @default.
• W2916033262 cites W2062359643 @default.
• W2916033262 cites W2097065650 @default.
• W2916033262 cites W2098008729 @default.
• W2916033262 cites W2102994534 @default.
• W2916033262 cites W2104391911 @default.
• W2916033262 cites W2113676816 @default.
• W2916033262 cites W2119852447 @default.
• W2916033262 cites W2122696108 @default.
• W2916033262 cites W2146901298 @default.
• W2916033262 cites W2159205789 @default.
• W2916033262 cites W2163589808 @default.
• W2916033262 cites W2171484293 @default.
• W2916033262 cites W2196465006 @default.
• W2916033262 cites W2277579395 @default.
• W2916033262 cites W2489117760 @default.
• W2916033262 cites W2742281288 @default.
• W2916033262 cites W4254810649 @default.
• W2916033262 cites W4363260 @default.
• W2916033262 doi "https://doi.org/10.1002/pds.4746" @default.
• W2916033262 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30779266" @default.
• W2916033262 hasPublicationYear "2019" @default.
• W2916033262 type Work @default.
• W2916033262 sameAs 2916033262 @default.
• W2916033262 citedByCount "5" @default.
• W2916033262 countsByYear W29160332622019 @default.
• W2916033262 countsByYear W29160332622020 @default.
• W2916033262 countsByYear W29160332622021 @default.
• W2916033262 countsByYear W29160332622022 @default.
• W2916033262 crossrefType "journal-article" @default.
• W2916033262 hasAuthorship W2916033262A5056369963 @default.
• W2916033262 hasAuthorship W2916033262A5059182035 @default.
• W2916033262 hasAuthorship W2916033262A5089899558 @default.
• W2916033262 hasConcept C121608353 @default.
• W2916033262 hasConcept C126322002 @default.
• W2916033262 hasConcept C134018914 @default.
• W2916033262 hasConcept C142454548 @default.
• W2916033262 hasConcept C167135981 @default.
• W2916033262 hasConcept C201903717 @default.
• W2916033262 hasConcept C207103383 @default.
• W2916033262 hasConcept C2777180221 @default.
• W2916033262 hasConcept C2778854520 @default.
• W2916033262 hasConcept C2778881409 @default.
• W2916033262 hasConcept C2779306644 @default.
• W2916033262 hasConcept C2780323712 @default.
• W2916033262 hasConcept C2910068830 @default.
• W2916033262 hasConcept C44249647 @default.
• W2916033262 hasConcept C50382708 @default.
• W2916033262 hasConcept C555293320 @default.
• W2916033262 hasConcept C67774102 @default.
• W2916033262 hasConcept C71924100 @default.
• W2916033262 hasConcept C77350462 @default.
• W2916033262 hasConcept C82789193 @default.
• W2916033262 hasConceptScore W2916033262C121608353 @default.
• W2916033262 hasConceptScore W2916033262C126322002 @default.
• W2916033262 hasConceptScore W2916033262C134018914 @default.
• W2916033262 hasConceptScore W2916033262C142454548 @default.
• W2916033262 hasConceptScore W2916033262C167135981 @default.
• W2916033262 hasConceptScore W2916033262C201903717 @default.
• W2916033262 hasConceptScore W2916033262C207103383 @default.
• W2916033262 hasConceptScore W2916033262C2777180221 @default.
• W2916033262 hasConceptScore W2916033262C2778854520 @default.
• W2916033262 hasConceptScore W2916033262C2778881409 @default.
• W2916033262 hasConceptScore W2916033262C2779306644 @default.
• W2916033262 hasConceptScore W2916033262C2780323712 @default.
• W2916033262 hasConceptScore W2916033262C2910068830 @default.
• W2916033262 hasConceptScore W2916033262C44249647 @default.
• W2916033262 hasConceptScore W2916033262C50382708 @default.
• W2916033262 hasConceptScore W2916033262C555293320 @default.
• W2916033262 hasConceptScore W2916033262C67774102 @default.
• W2916033262 hasConceptScore W2916033262C71924100 @default.
• W2916033262 hasConceptScore W2916033262C77350462 @default.
• W2916033262 hasConceptScore W2916033262C82789193 @default.
• W2916033262 hasFunder F4320334576 @default.
• W2916033262 hasIssue "4" @default.

• next